Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fibrinogen Degradation Speed as a Predictor of Major Bleeding Complications During Catheter Directed Thrombolysis in Patients with Acute Lower Limb Ischaemia.
Leenstra B, van Ginkel DJ, Huitema ADR, Verhoeven BAN, Vonken EJ, de Borst GJ. Leenstra B, et al. Among authors: huitema adr. Eur J Vasc Endovasc Surg. 2021 May;61(5):861-862. doi: 10.1016/j.ejvs.2020.12.010. Epub 2021 Feb 11. Eur J Vasc Endovasc Surg. 2021. PMID: 33583709 Free article. No abstract available.
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
van Hasselt JGC, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JHM, Beijnen JH, Huitema ADR, Amant F. van Hasselt JGC, et al. Among authors: huitema adr. Ann Oncol. 2014 Oct;25(10):2059-2065. doi: 10.1093/annonc/mdu140. Epub 2014 Apr 8. Ann Oncol. 2014. PMID: 24713311 Free article.
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.
de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. de Vries Schultink AH, et al. Eur J Clin Pharmacol. 2016 Jun;72(6):645-53. doi: 10.1007/s00228-016-2030-4. Epub 2016 Feb 26. Eur J Clin Pharmacol. 2016. PMID: 26915815 Free PMC article. Review.
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE. van Waalwijk van Doorn-Khosrovani SB, et al. Among authors: huitema adr. Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. Ann Oncol. 2019. PMID: 31038154 Free article. No abstract available.
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.
Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, de Vries N, Rosing H, Otten H, Vulink AJE, Desar IME, Imholz ALT, Gelderblom H, van Erp NP, Beijnen JH, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: huitema adr. Ann Oncol. 2022 Oct;33(10):1071-1082. doi: 10.1016/j.annonc.2022.06.010. Epub 2022 Jun 28. Ann Oncol. 2022. PMID: 35777707 Free article.
542 results